Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (2): 189-193    DOI: 10.31083/j.ceog.2020.02.5043
Original Research Previous articles | Next articles
Pregnancy outcomes and risk factors in pregnant women with systemic lupus erythematosus
Li Li Zhang1, Hua Shu2, *(), Shuai Zhang3, Tian Tian Wang3, Lan Lan Zhang4
1Department of Rheumatology Immunologys, Affiliated Hospital of Jining Medical College, Jining, P.R. China
2Department of Obstetrics, Affiliated Hospital of Jining Medical College, Jining, P.R. China
3Department of Infection, Jining Infectious Disease Hospital, Jining, P.R. China
4Department of Internal Medicine, Jining Psychiatric Hospital, Jining, P.R. China
Download:  PDF(2264KB)  ( 271 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  Objective: To analyze the pregnancy outcomes and risk factors in pregnant women with systemic lupus erythematosus (SLE), for providing a reference for the clinical diagnosis and treatment of the SLE. Materials and Methods: Seventy-eight SLE patients with 82 pregnancies were enrolled in this study. The general information of patients, maternal history data, clinical symptoms, and laboratory examination data one to three months before pregnancy, during pregnancy, at delivery and after childbirth, drug treatment, and pregnancy outcomes were collected. The single factor and logistic regression analyses of the risk factors related to SLE with deterioration and fetal loss were performed. Results: The single-factor analysis showed that there was significant difference in complement 3, 24-hour urinary protein, anti-dsDNA antibody, anti-CL antibody, pre-pregnancy prednisone dose, and SLE disease activity index (SLEDAI) between SLE with deterioration group and SLE without deterioration group, respectively (p < 0.05 or p < 0.01), with significant difference in complement 3, combined antiphospholipid syndrome (APS), SLEDAI, and SLE deterioration during pregnancy between fetal loss group and live birth group, respectively (p < 0.01). The multi-factor regression analysis showed that, the complement 3 and SLEDAI were the main risk factors of SLE with deterioration during pregnancy, and the combined APS and SLEDAI were the main risk factors of fetal loss. Conclusion: The pregnancy has a high risk in women with SLE. The complement 3 and SLEDAI are the main risk factors of SLE with deterioration during pregnancy, and the combined APS and SLEDAI are the main risk factors of fetal loss. The reasonable and effective strategies should be formulated based on these factors, in order to reduce the risk of adverse pregnancy outcomes.
Key words:  Systemic lupus erythematosus      Pregnancy      Outcomes      Risk factors     
Published:  15 April 2020     
*Corresponding Author(s):  Hua Shu     E-mail:  shuhuajn@126.com

Cite this article: 

Li Li Zhang, Hua Shu, Shuai Zhang, Tian Tian Wang, Lan Lan Zhang. Pregnancy outcomes and risk factors in pregnant women with systemic lupus erythematosus. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 189-193.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2020.02.5043     OR     https://ceog.imrpress.com/EN/Y2020/V47/I2/189

Table 1  — Single-factor analysis of factors for SLE with deterioration during pregnancy.
Index SLE with deterioration SLE without deterioration t/χ2 p
n 31 51
Age (years) 25.23 ± 3.14 26.12 ± 3.46 -1.169 0.246
Disease course (years) 5.45 ± 2.37 4.67 ± 1.98 1.604 0.113
WBC (× 109 /L) 7.13 ± 2.45 7.67 ± 1.64 -1.196 0.235
Hemoglobin (g/L) 92.59 ± 26.03 88.12 ± 19.26 0.890 0.376
Platelets (× 109 /L) 156.33 ± 34.58 163.73 ± 28.52 -1.050 0.297
ESR (mm/h) 21.68 ± 5.78 19.56 ± 5.18 1.720 0.089
Serum albumin (g/L) 28.93 ± 5.12 30.94 ± 6.27 -1.505 0.136
Serum globulin (g/L) 30.93± 5.68 32.45 ± 4.33 -1.368 0.175
CRP (mg/L) 3.15 ± 0.67 2.87 ± 0.78 1.660 0.101
IgG (g/L) 16.94 ± 3.78 17.33 ± 2.56 -0.557 0.580
IgA (g/L) 1.87 ± 0.56 1.99 ± 0.58 -0.920 0.360
IgM (g/L) 1.11 ± 0.31 1.25 ± 0.38 -1.730 0.088
Complement 3 (g/L) 0.81 ± 0.26 0.98 ± 0.22 -3.166 0.002
Complement 4 (g/L) 0.13 ± 0.05 0.15 ± 0.06 -1.555 0.124
24h UP (g/24h) 0.99 ± 0.34 0.74 ± 0.38 3.003 0.004
Positive anti-dsDNA antibody [n(%)] 13 (41.94) 8 (15.67) 6.9732 0.008
Positive anti-CL antibody [n(%)] 18 (58.06) 15 (29.41) 6.5822 0.010
Pre-pregnancy prednisone dose [n(%)] 6.762 0.009
≥ 10 mg/day 16 (51.61) 12 (23.53)
< 10 mg/day 15 (48.39) 39 (76.47)
SLEDAI [n(%)] 8.701 0.003
≥ 5 points 18 (58.06) 13 (25.49)
< 5 points 13 (41.94) 38 (74.51)
Table 2  — Multi-factor regression analysis of factors for SLE with deterioration during pregnancy.
Variable B S.E. Wald df Sig. Exp(B) 95% C.I. for Lower EXP(B)
Upper
Complement 3 5.341 2.060 6.721 1 0.012 208.771 3.681 11841.894
24h UP -1.679 2.133 0.619 1 0.431 0.187 0.003 12.210
Anti-dsDNA antibody 2.872 1.498 3.675 1 0.055 17.672 0.938 333.091
Anti-CL antibody 0.165 0.145 1.288 1 0.256 1.179 0.887 1.569
Pre-pregnancy prednisone dose 3.127 2.017 2.403 1 0.121 22.794 0.438 1187.525
SLEDAI 4.263 1.673 6.491 1 0.011 71.045 2.674 1887.362
Constant -14.828 7.661 3.746 1 0.053 0.000
Figure 1.  Receiver operating characteristic curves of complement 3 and SLEDAI for predicting systemic lupus erythematosus with deterioration. SLEDAI: systemic lupus erythematosus disease activity index.

Figure 2.  Receiver operating characteristic curves of combined APS and SLEDAI for predicting fetal loss. APS: antiphospholipid syndrome; SLEDAI: systemic lupus erythematosus disease activity index.

Table 3  — Single-factor analysis of factors for fetal outcome.
Index Fetal loss Live birth t/χ2 p
n 27 55
Age (years) 26.32 ± 3.26 25.34 ± 3.18 1.301 0.197
Disease course (years) 5.61 ± 2.48 4.49 ± 2.72 1.802 0.075
WBC (× 109 /L) 7.19 ± 2.66 7.55 ± 1.87 -0.710 0.480
Hemoglobin (g/L) 93.44 ± 22.67 87.89 ± 21.33 1.085 0.281
Platelets (× 109 /L) 161.45 ± 35.77 176.67 ± 39.83 -1.679 0.097
ESR (mm/h) 21.78 ± 4.83 19.94 ± 4.79 1.630 0.107
Serum albumin (g/L) 28.47 ± 6.72 30.37 ± 5.83 -1.318 0.191
Serum globulin (g/L) 29.97 ± 6.77 31.95 ± 4.84 -1.521 0.132
CRP (mg/L) 3.12 ± 0.67 2.79 ± 0.85 1.764 0.082
IgG (g/L) 16.57 ± 3.67 17.57 ± 2.84 -1.358 0.178
IgA (g/L) 1.92 ± 0.54 1.98 ± 0.52 -0.485 0.629
IgM (g/L) 1.09 ± 0.32 1.24 ± 0.38 -1.765 0.081
Complement 3 (g/L) 0.77 ± 0.22 0.93 ± 0.25 -2.829 0.006
Complement 4 (g/L) 0.14 ± 0.06 0.16 ± 0.05 -1.592 0.115
24h UP (g/24h) 0.94 ± 0.31 0.79 ± 0.42 1.647 0.104
Positive anti-dsDNA antibody [n(%)] 8 (29.63) 13 (23.64) 0.341 0.559
Positive anti-CL antibody [n(%)] 14 (51.85) 19 (34.55) 2.256 0.133
Combined APS 7 (25.93) 2 (3.64) 9.208 0.002
Pre-pregnancy prednisone dose [n(%)] 1.898 0.168
≥ 10 mg/day 12 (44.44) 16 (29.09)
< 10 mg/day 16 (55.56) 39 (70.91)
SLEDAI [n(%)] 7.880 0.005
≥ 5 points 16 (59.26) 15 (27.27)
< 5 points 11 (40.74) 40 (72.73)
SLE deterioration [n(%)] 16 (59.26) 15 (27.27) 7.880 0.005
Table 4  — Multi-factor regression analysis of factors for fetal loss.
Variable B S.E. Wald df Sig. Exp(B) 95% C.I. for Lower EXP(B)
Upper
Complement 3 2.183 1.560 1.958 1 0.162 8.869 0.417 188.549
Combined APS 3.269 1.523 4.610 1 0.032 26.296 1.330 519.958
SLEDAI 4.377 1.562 7.854 1 0.005 79.612 3.728 1699.958
SLE deterioration 0.086 0.135 0.409 1 0.523 1.090 0.837 1.420
Constant -8.178 5.950 1.889 1 0.169 0.000
[1] Iozza I., Cianci S., Di Natal, A., Garofalo, G., Giacobb, A.M., Giorgio, E., et al.: “Update on systemic lupus erythematosus pregnancy”. J. Prenat. Med., 2010, 4, 67.
pmid: 22439065
[2] Wang J., Nuite M., McAlindon, T.E.: “Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus”. Lupus, 2010, 19, 734.
doi: 10.1177/0961203309359517 pmid: 20305046
[3] Jara L.J., Medina G., Saavedra M.A., Vera-Lastra, O., Torres-Aguilar, H., Navarro, C. et al.: “Prolactin has a pathogenic role in systemic lupus erythematosus”. Immunol. Res., 2017, 65, 5123.
[4] Cravioto M.D., Durand-Carbajal, M., Jiménez-Santana, L., Lara-Reyes, P., Seuc, A.H., Sánchez-Guerrero, J.: “Efficacy of estrogen plus progestin on menopausal symptoms in women with systemic lupus erythematosus: a randomized, double-blind, controlled trial”. Arthritis Care Res., 2011, 63, 1654.
doi: 10.1002/acr.20608
[5] Aikawa N.E., Sallum A.M., Pereira R.M., Suzuki L., Viana V.S., Bonfá E., et al.: “Subclinical impairment of ovarian reserve in juvenile systemic lupus erythematosus after cyclophosphamide therapy”. Clin. Exp. Rheumatol., 2012, 30, 445.
[6] Ostensen, M., Clowse, M.: “Pathogenesis of pregnancy complications in systemic lupus erythematosus”. Curr. Opin. Rheumatol., 2013, 25, 591.
doi: 10.1097/BOR.0b013e328363ebf7
[7] Gladman D.D., Ibañez D., Urowitz M.B.: “Systemic lupus erythematosus disease activity index 2000”. J. Rheumatoly., 2002, 29, 288.
[8] Ruiz-Irastorza, G., Khamashta, M.A., Gordon, C., Lockshin, M.D., Johns, K.R., Sammaritano, L., et al.: “Measuring systemic lupus erythematosus activity during pregnancy: validation of the lupus activity index in pregnancy scale”. Arthritis Rheum., 2004, 51, 78.
doi: 10.1002/art.20081 pmid: 14872459
[9] Cortés-Hernández, J., Ordi-Ros, J., Paredes, F., Casellas, M., Castillo, F., Vilardell-Tarres, M., : “Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies”. Rheumatology (Oxford), 2002, 41, 643.
doi: 10.1093/rheumatology/41.6.643
[10] Tedeschi S.K., Guan H., Fine A., Costenbader K.H., Bermas B.: “Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes”. Clin. Rheumatol., 2016, 35, 1725.
doi: 10.1007/s10067-016-3270-5 pmid: 27166627
[11] Götestam Skorpen, C., Lydersen, S., Gilboe, I.M., Skomsvoll, J.F., Salvesen, K.Å., Palm, Ø., et al.: “Disease activity during pregnancy and the first year postpartum in women with systemic lupus erythematosus”. Arthritis Care Res. (Hoboken), 2017, 69, 1201.
[12] Lu Q., Yang H., Qu Y., Ding Y., Kang X., Pu, X.: “Relationship between clinical systemic lupus erythematosus symptoms and indexes of blood, renal function, liver function and immunology”. W. Indian. Med. J., 2017.Published ahead-of-print 10.7727/wimj.2017.148.
doi: 10.7727/wimj.2016.052 pmid: 27398602
[13] Friedman A.S, Folkert V., Khan G.A.:“Recurrence of systemic lupus erythematosus in a hemodialysis patient presenting as a unilateral abducens nerve palsy”. Clin. Nephrol., 1995, 44. 3389.
[14] Jara L.J., Medina G., Cruz-Dominguez, P., Navarro, C., Vera-Lastra, O., Saavedra, M.A.: “Risk factors of systemic lupus erythematosus flares during pregnancy”. Immunol. Res., 2014, 60, 184.
doi: 10.1007/s12026-014-8577-1
[15] Schwarz, E.B., Manzi, S.: “Risk of unintended pregnancy among women with systemic lupus erythematosus”. Arthritis Rheum., 2008, 59, 863.
doi: 10.1002/art.23712 pmid: 18512717
[16] Drenkard C., Villa A.R., Reyes E., Abello M., Alarcón-Segovi D., : “Vasculitis in systemic lupus erythematosus”. Lupus, 1997, 6, 235.
doi: 10.1177/096120339700600304 pmid: 9104729
[17] Yuan W., DiMartino, S.J., Redecha, P.B., Ivashkiv, L.B., Salmon, J.E., : “Systemic lupus erythematosus monocytes are less responsive to interleukin-10 in the presence of immune complexes”. Arthritis Rheum., 2011, 63, 212.
doi: 10.1002/art.30083 pmid: 20954190
[18] Kwok L.W., Tam L.S., Zhu T., Leung Y.Y., Li E.: “Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus”. Lupus, 2011, 20, 829.
doi: 10.1177/0961203310397967
[19] Friedman D.M.: “Fetal echocardiography in the assessment of lupus pregnancies”. Am. J. Reprod. Immunol., 1992, 28, 164.
doi: 10.1111/j.1600-0897.1992.tb00782.x pmid: 1285870
[20] Clowse M.E., Magder L.S., Witter F., Petri M.: “Early risk factors for pregnancy loss in lupus”. Obstet. Gynecol., 2006, 107, 293.
doi: 10.1097/01.AOG.0000194205.95870.86 pmid: 16449114
[21] Tian X., Li M., Ye Z., Zhang X., Liu S., Wu L., et al.: “Related factors of fetal loss in Chinese women with systemic lupus erythematosus: data from Chinese SLE Treatment and Research Group registry IV”. Int. J. Rheum. Dis., 2015, 18, 654.
doi: 10.1111/1756-185X.12542 pmid: 25546582
[22] Mankee A., Petri M., Magder L, S.: “Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss”. Lupus Sci. Med., 2015, 2, e000095.
doi: 10.1136/lupus-2015-000095 pmid: 26688740
[1] Amanda M. Wang, Alan J. Lee, Shannon M. Clark. The effects of overweight and obesity on pregnancy-related morbidity[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 999-1009.
[2] Leen Van den Eeden, Greet Leysens,Dominique Mannaerts, Yves Jacquemyn. Air pollution: cardiovascular and other negative effects on pregnancy: a narrative review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1010-1016.
[3] Xin Du, Qian Zou, Yu-Lan Liu. Transumbilical single-hole laparoscopic treatment of cesarean scar pregnancy by uterine artery pre-ligation: a report of 4 cases[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1044-1047.
[4] Marcelo Epsztein Kanczuk, Nicholas J Lightfoot, Alison Pighills, Antony Ji, Casey Steele, Daniel Bartlett. The time to perform spinal or general anaesthesia in COVID-19 positive parturients requiring emergency caesarean delivery: a prospective crossover simulation study[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1099-1106.
[5] Noor Hazim Abdulkareem, Elham Hazeim Abdulkareem. SARS-CoV-2 detection in pregnant and non-pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1141-1145.
[6] Min Jung Kim, Hee-Sook Lim, Hae-Hyeog Lee, Tae-Hee Kim, Yongsoon Park. Dietary assessment, nutrition knowledge, and pregnancy outcome in high-risk pregnant Korean women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1178-1185.
[7] Neha Sethi, Ann Gee Tan, Maherah Kamarudin, Sofiah Sulaiman. Successful delivery of a twin pregnancy with complete hydatidiform mole and coexistent live fetus: a case report and review of literature[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(5): 1232-1247.
[8] Luca Roncati, Greta Gianotti, Elisa Ambrogi, Giovanna Attolini. COVID-19 in pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 778-780.
[9] Silvia Amodeo, Giulia Bonavina, Anna Seidenari, Paolo Ivo Cavoretto, Antonio Farina. Real-world implementation and adaptation to local settings of first trimester preeclampsia screening in Italy: a systematic review[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 812-819.
[10] Yu Deng, Zhan-Hui Ou, Min-Na Yin, Pei-Ling Liang, Zhi-Heng Chen, Abraham Morse, Ling Sun. Age and anti-Műllerian hormone: prediction of cumulative pregnancy outcome in in vitro fertilization with diminished ovarian reserve[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 835-841.
[11] Kuntharee Traisrisilp, Supatra Sirichotiyakul, Fuanglada Tongprasert, Kasemsri Srisupundit, Suchaya Luewan, Phudit Jatavan, Sirinart Sirilert, Theera Tongsong. Increased nuchal translucency and fetal outcomes: a population-based study in Thailand[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 860-866.
[12] Serdar Balci. The effect of ultraviolet index measurements on levels of vitamin D andinflammatory markers in pregnant women[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 888-892.
[13] Anna M. Rubinshtein, Oleg V. Golyanovskiy. Obstetric outcomes in women of advanced maternal age after assisted reproduction[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 893-900.
[14] Qian Hu, Mohammed Sharooq Paramboor, Tao Guo. Diagnosis and management of intramural ectopic pregnancy[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 974-979.
[15] Ovadya Rosenbluh, Asnat Walfisch. Birth defects associated with obesity[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 472-477.
No Suggested Reading articles found!